Clinical research progress on radiopharmaceuticals imaging targeting epidermal growth factor receptor / 中华核医学与分子影像杂志
Chinese Journal of Nuclear Medicine and Molecular Imaging
; (6): 428-432, 2022.
Article
in Zh
| WPRIM
| ID: wpr-957156
Responsible library:
WPRO
ABSTRACT
Epidermal growth factor receptor (EGFR) plays an important role in the development and occurrence of a variety of malignant tumors. Molecular targeted therapy for EGFR is in the ascendant. Molecular imaging can reveal the expression of EGFR and its mutations in vivo. The molecular probes labeled with 89Zr, 11C and 18F are used for imaging and the main research is about tyrosine kinase inhibitors labeled with 11C. PET is used to visualize EGFR expression and mutations in vivo, which can noninvasively screen patients suitable for targeting treatment and evaluate efficacy. This paper reviews the clinical researches and trials of these probes, and summarizes the clinical value of imaging methods, hoping to provide the evidence for clinical translation and application in the future.
Full text:
1
Database:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Nuclear Medicine and Molecular Imaging
Year:
2022
Document type:
Article